Menu
Close
Information on this page is aligned to the Great Britain Summary of Product Characteristics (SmPC) for each formulation.
Prescribing Information can be found in the top right corner of the website. Information about adverse event reporting can be found towards the bottom of this page.
Therapeutic indications:
The information on this website relates to storage, preparation and administration of COMIRNATY vaccines used as part of the UK National Immunisation Programme.
For information regarding private provisions of COMIRNATY vaccines please visit PfizerPro:
www.Pfizerpro.co.uk/medicine/comirnaty
For more information relating to Pfizer’s vaccines and related therapy areas, including clinical publications and resources, as well as assets relating to particular at-risk groups, please visit:
https://pfizermedical.pfizerpro.co.uk/vaccines
There are several formulations of COMIRNATY vaccine used as part of the current programme. These are summarised in the table below, with more information on the product pages. To verify that you have selected the correct vaccine, observe the key aspects of the pack and vial label for the formulation before administration.
Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the batch/Lot number if available.
Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.
COMIRNATY is a Prescription Only Medicine which has been centrally procured by the UK government.
Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH
COMIRNATY, COMIRNATY JN.1, COMIRNATY Omicron XBB.1.5, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.
©2024 Pfizer Inc. All rights reserved.PP-CMR-GBR-0711. November 2024
*Healthcare Professionals ** Other Relevant Decision Makers
The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in the United Kingdom.
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427.
The products discussed may have different product labelling in other countries.
For Healthcare Professionals* and Other Relevant Decision Makers** only
This website is not intended for patients or for members of the general public. The website contains promotional content.
I confirm that I am a Healthcare Professional* or Other Relevant Decision Maker** resident in the United Kingdom.
If you select Yes – Great Britain: you will be directed to the Great Britain*** homepage. Information on this page is aligned to the Summary of Product Characteristics (SmPC) for Great Britain.
If you select Yes – Northern Ireland: you will be directed to the Northern Ireland homepage. Information on this page is aligned to the SmPC for Northern Ireland.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition of Healthcare Professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
**The ABPI Code definition of ‘Other Relevant Decision Makers’ particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
*** Great Britain includes England, Scotland and Wales.
PP-CMR-GBR-0400 June 2023